These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 25728587)

  • 1. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
    Reinisch W; Colombel JF; Sandborn WJ; Mantzaris GJ; Kornbluth A; Adedokun OJ; Miller M; Tang KL; Rutgeerts P; Cornillie F
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):539-547.e2. PubMed ID: 25245629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission.
    Lin X; Qiu Y; Feng R; Chen B; He Y; Zeng Z; Zhang S; Chen M; Mao R
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00135. PubMed ID: 32463625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
    Colombel JF; Adedokun OJ; Gasink C; Gao LL; Cornillie FJ; D'Haens GR; Rutgeerts PJ; Reinisch W; Sandborn WJ; Hanauer SB
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1525-1532.e1. PubMed ID: 30267864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W; Wang Y; Oddens BJ; Link R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
    Bouguen G; Sninsky C; Tang KL; Colombel JF; DʼHaens G; Kornbluth A; Mantzaris GJ; Rachmilewitz D; Reinisch W; Rutgeerts P; Molenda M; Jannekevan der Woude C; Sandborn WJ
    Inflamm Bowel Dis; 2015 Mar; 21(3):606-14. PubMed ID: 25581826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.
    Fan R; Zhong J; Wang ZT; Li SY; Zhou J; Tang YH
    World J Gastroenterol; 2014 Oct; 20(39):14479-87. PubMed ID: 25339835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
    Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Colombel JF; Reinisch W
    J Crohns Colitis; 2021 Oct; 15(10):1649-1657. PubMed ID: 33693522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological therapy in the management of recent-onset Crohn's disease: why, when and how?
    Löwenberg M; Peppelenbosch M; Hommes D
    Drugs; 2006; 66(11):1431-9. PubMed ID: 16906776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.